Recent Quotes

My Watchlist

Indicators

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.610 +0.060 (+3.87%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	322,794
Open	1.540
Bid (Size)	1.500 (4)
Ask (Size)	1.610 (10)
Prev. Close	1.550
Today's Range	1.510 - 1.660
52wk Range	1.070 - 4.620
Shares Outstanding	80,817,079
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ProQR Announces First Quarter 2025 Operating and Financial Results

May 08, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 02, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

Performance

YTD	-41.2%	-41.2%
1 Month	+34.2%	+34.2%
3 Month	-28.4%	-28.4%
6 Month	-57.3%	-57.3%
1 Year	-19.5%	-19.5%

More News

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

May 01, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

April 14, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Year End 2024 Operating and Financial Results

March 13, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

February 12, 2025

Via Benzinga

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

December 11, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

December 10, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

December 05, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

November 18, 2024

Via Benzinga

ProQR Announces Third Quarter 2024 Operating and Financial Results

November 07, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

October 29, 2024

Via Benzinga

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

October 25, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

October 22, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

October 22, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

October 17, 2024

Via Benzinga

Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

October 17, 2024

Via Benzinga

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

October 07, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

September 10, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024

August 12, 2024

Via InvestorPlace

ProQR Announces Second Quarter 2024 Operating and Financial Results

August 08, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit

June 18, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces First Quarter 2024 Operating and Financial Results

May 09, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

May 08, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

April 23, 2024

From ProQR Therapeutics N.V.

Via GlobeNewswire

Frequently Asked Questions

Is ProQR Therapeutics N.V. - Ordinary Shares publicly traded?

Yes, ProQR Therapeutics N.V. - Ordinary Shares is publicly traded.

What exchange does ProQR Therapeutics N.V. - Ordinary Shares trade on?

ProQR Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares?

The ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares is PRQR on the Nasdaq Stock Market

What is the current price of ProQR Therapeutics N.V. - Ordinary Shares?

The current price of ProQR Therapeutics N.V. - Ordinary Shares is 1.610

When was ProQR Therapeutics N.V. - Ordinary Shares last traded?

The last trade of ProQR Therapeutics N.V. - Ordinary Shares was at 05/09/25 04:00 PM ET

What is the market capitalization of ProQR Therapeutics N.V. - Ordinary Shares?

The market capitalization of ProQR Therapeutics N.V. - Ordinary Shares is 130.12M

How many shares of ProQR Therapeutics N.V. - Ordinary Shares are outstanding?

ProQR Therapeutics N.V. - Ordinary Shares has 130M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.